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Background: Expression of circulating serum microRNAs has not been studied in a cohort of patients with 
papillary renal cell carcinoma (pRCC) so far. We hypothesized that miRNA deregulation in malignant tissue 
is reflected in serum and could be used for non-invasive diagnosis of pRCC as well as differentiation between 
type 1 and type 2 pRCC.
Methods: We selected 11 differentially regulated miRNAs from the Cancer Genome Atlas (TCGA) pRCC 
data set as potential serum validation candidates. Serum miRNA expression was determined by qRT-PCR in 
a total of 34 pRCC type 1, 33 pRCC type 2 and 33 control subjects of three german high-volume medical 
centers.
Results: Heatmap and principal component analysis showed that miRNA expression did not cluster 
the samples into distinct sample groups and that miRNA levels did not significantly discriminate healthy 
individuals from patients with pRCC, nor between patients with type 1 and type 2 pRCC. However, miR-
21-5p levels were significantly increased in patients with advanced pRCC (>pT3, and/or pN+ and/or pM+) 
in comparison to localized pRCC. Moreover, adding the expression of miR-210-3p, which was significantly 
down-regulated in localized pRCC sera in comparison to healthy sera, additionally increased diagnostic 
accuracy in our study cohort.
Conclusions: In our multicenter cohort, we were not able to identify a single miRNA serum marker for 
pRCC including its subclasses. However, our study revealed that miR-21-5p levels were elevated in advanced 
disease (with added diagnostic accuracy via addition of miR-210-3p expression), proposing these two miRs as 
potential biomarkers in pRCC.
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Introduction
Accounting for about 3% of adult malignancies, renal 
cell carcinoma (RCC) is the most common neoplasm of 
the adult kidney (1). Additionally, it bears a comparably 
high mortality rate of up to 40%, which stresses the 
clinical importance of this entity (2). Papillary renal cell 
carcinoma (pRCC) accounts for 15–20% of all RCCs 
and represents a heterogeneous disease regarding disease 
progression, therapy response and patient outcome (3-5). 
To more accurately stratify aggressive disease from indolent 
tumours, Delahunt and Eble proposed a morphological 
subtyping of pRCCs in 1997 into two subgroups: first, 
there is type 1 pRCC, which is often found multifocal, 
holding small cuboid cells arranged into layers and a 
predominantly indolent clinical course; on the contrary, 
there is type 2 pRCC, with voluminous eosinophilic cells 
in pseudostratification patterns and a more aggressive 
clinical behaviour (6). This subclassification pattern and its 
prognostic value was confirmed in various clinical studies (7).
Unfortunately, besides morphological characterization, 
there have been no investigations whether serum biomarkers 
might be useful to detect and/or distinguish pRCC and its 
subtypes from other malign entities of the kidney. MiRNAs 
are predestined for this particular task: their expression 
profiles not only allow distinguishing malignant and non-
malignant tissue, but also different tumor entities (8). 
MiRNAs are circulating in a cell-free form in blood (9-11), 
very likely in exosomes which protect them against RNase 
degradation (9,11). MiRNA-signatures in blood are similar 
in men and women, as well as individuals of different 
age (10). Furthermore, miRNA expression levels are 
comparable both in plasma and serum, and are not disturbed 
by repeated freeze/thaw cycles as well as by prolonged 
storage at room temperature (11).
So far, circulating miRNAs have not been investigated 
in patients with pRCC regarding their potential diagnostic 
(compared to healthy controls) or discriminative (regarding 
the two subtypes) implications. Several groups analysed 
miRNA-expression in pRCC tissue specimen with 
conflicting results (12-14). We therefore designed our study 
to identify and validate potential miRNA serum-candidates 
in a multicenter setting.
Methods
Ethics statement
This study was approved by the local human research 
ethics committees of the three participating medical centres 
(Charité Berlin: No. EA1/134/12, University of Bonn: No. 
036/08, University of Würzburg: No. 136/08) and was 
conducted according to the standards set by the declaration 
of Helsinki; all patients provided written informed consent 
before being enrolled.
Patients and serum samples
We collected preoperative serum samples of n=67 patients 
suffering from pRCC, divided into n=34 pRCC type 1 and 
n=33 pRCC type 2 cases who consecutively underwent 
surgery at the participating centers between 2008–2014. 
The clinical and pathological patient characteristics are 
shown in Table 1. Sera of healthy subjects (n=33) not 
suffering from urological or other malignancies were used 
as controls.
RNA extraction, qRT-PCR and normalization
To centralize sample processing, RNA extraction and qRT-
PCR for microRNAs let-7b, miR-10a-3p, miR-10b-5p, 
miR-21-5p, miR-126-3p, miR-127-3p, miR-142-3p, miR-
155-5p, -199a-3p, miR-210-3p and miR-425-5p were 
executed by Exiqon RNA services (http://www.exiqon.
com). Samples were spiked with UniSp2, UniSp4, and 
UniSp to exclude technical errors during RNA isolation and 
cDNA synthesis, haemolysis was controlled by measuring 
the optical density of the samples at 414 nm (cut-off value 
0.3) in a monochromator and by calculating the ΔCt of 
miR-23a-3p (unaffected by haemolysis) and miR-451a-
5p (expressed in erythrocytes). The geometric mean of 
miR-23a-3p, miR-191-5p and miR-103a-3p was used for 
normalization.
Statistics and data analysis
Statistical analysis was performed using R 3.10 (URL: 
http://www.r-project.org), figures were drawn either with R 
or Graphpad Prism 7.
Pearson’s chi-square test was used to realize intergroup 
comparison. If two means of normally distributed data 
had to be compared, two-sided unpaired student’s t-test 
was used. More than two group means were differentiated 
by analysis of variance (ANOVA) with post-hoc testing 
(Tukey’s test) if significant differences occurred. Principal 
component analysis (PCA), hierarchical clustering, heat 
maps and correlation matrices were realized with the 
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packages corrplot, Amelia, ROCR, My.stepwise, ggplot2, 
limma. lattice, and gplots. Significant associations were set 
as P≤0.05 (*).
Results
Candidate miRNA selection and quality control
Potential miRNAs were identified based on their elevated 
expression in pRCC, their elevated expression in either type 
1 or type 2 pRCC and high overall expression levels on the 
basis of previously published results (12-14). To allow the 
identification of a robust and sensitive serum marker, we 
further selected only miRNAs that were already present in 
serum in detectable levels in healthy controls (11,15). An 
overview of the experimental setup is shown in Figure 1A.
Of the selected miRNAs, miR-210-3p, miR-21-5p were 
previously described as serum markers (13,14), whereas 
selection of let-7b-3p, miR-10a-5p, miR-10b-5p, miR-126-
3p, miR-127-3p, miR-142-3p, miR-155-5p, miR-199a-
3p, and miR-425-5p was solely based on elevated tissue 
expression. The miRNAs let-7b, miR-10a-5p, miR-10b-5p, 
miR-126-3p, miR-127-3p, and miR-199a-3p, and miR-425-
5p were deregulated in pRCC type 1 vs. pRCC type 2 (12).
To ensure quality of the samples, we tested for 
haemolysis by comparing the expression values of miR-
23, which is not expressed in erythrocytes and thus not 
influenced by haemolysis and miR-451, which is highly 
expressed in erythrocytes. We further correlated expression 
of all miRNAs with the serum haemolysis values and found 
that beside miR-451, miR-425-5p, and miR-210-3p were 
correlated with haemolysis in our samples (Figure 1B).
Table 1 Clinical characteristics of the patient cohort
Characteristics pRCC type 1 (n=34) pRCC type 2 (n=33) Both (n=67) P value
Patient age (years) 63.6 [35–78] 67.4 [46–81] 65 [35–81] 0.06
Sex
Male 30 (88.3%) 28 (84.9%) 58
Female 4 (11.7%) 5 (15.1%) 9 0.12
Tumor stage
pT1 27 (79.4%) 23 (69.8%) 50
pT2 4 (11.7%) 5 (15.1%) 9
pT3 3 (8.9%) 5 (15.1%) 8 fw ANOVA
pT4 0 (0%) 0 (0%) 0 0.132
Nodal stage
pN0 32 (94.1%) 24 (72.7%) 56
pN1 0 (0%) 5 (15.1%) 5 <0.01
pNX 2 (5.9%) 4 (12.2%) 6
Metastasis
pM0 33 (97.1%) 32 (94.1%) 65
pM1 1 (2.9%) 1 (5.9%) 2 0.1
WHO grading
G1 3 (8.9%) 1 (5.9%) 4
G2 29 (85.2%) 23 (64%) 52
G3 2 (5.9%) 8 (24.2%) 10 fw ANOVA
G4 0 (0%) 1 (5.9%) 1 0.141
fw ANOVA, forward analysis of variance.
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Comparability validation: normalized relative miR-
expression in relation to their center of origin
To validate comparability between the different samples 
in regard to the participating centres, we assessed the 
relative, normalized expression of all tested miRNAs and 
compared it in regard to the participating center. We found 
that one of the tested miRNAs was significantly differently 
expressed between the participating centres: miR-425-5p 
was significantly lower expressed in the Charité cohort in 
comparison to the other centers, and was therefore excluded 
from further analysis (Figure 1C).
Diagnostic power of miRNA expression in control vs. 
pRCC serum samples
We performed PCA of normalized miRNAs to identify 
relevant patients’ subgroups. However, miRNA expression 
was not able to cluster serum samples and the first two 
components were only able to explain 50% of the observed 
Figure 1 Candidate miRNA selection and quality control. (A) Description of the multicenter study design. (B) Haemolysis control for 
miR-23 (not expressed in erythrocytes), miR-451 (highly expressed in erythrocytes) and present haemoglobin (Hb) in the samples. (C) 
Normalized miR-expression in relation to the participating center.
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variance (Figure 2A). Likewise, supervised hierarchical 
clustering clearly shows that miRNA expression did 
not differentiate tumor samples from healthy controls 
(Figure 2B). The hierarchical clustering also indicated 
that no single miRNA was clearly differentially expressed 
between subtype 1 and subtype 2 sera (compare samples 
marked in red and blue), which was confirmed by direct 
comparison of each miRNAs in the pRCC samples and 
healthy controls (Figure S1).
In line with the PCA and hierarchical clustering, logistic 
regression analysis did not identify a single independent 
diagnostic marker and a model with all miRNA only 
resulted in an AUC of 0.71 in ROC analysis (Figure 2C).
Detailed expression data with regard to centres and 
subclasses are presented in Figure S1.
Association of miRNA expression and clinicopathological 
parameters in pRCC sera
To explore prognostic liabilities of the assessed miRNA 
expression profiles, we correlated the expression of 
all examined serum miRNAs with clinicopathological 
parameters, grouping patients into a localized (pT1-2 
and/or pN0 and/or pM0) or advanced (defined as pT>3 
and/or pN+ and/or pM+) disease group. miR-21-5p was 
significantly higher expressed in advanced samples in 
comparison to non-advanced samples and control sera in 
the Berlin cohort as well as in the cross cohort comparison 
(Figure 3) and showed a borderline significance in the 
Wurzburg cohort. As the Bonn cohort only contained 
two advanced disease sample, we did not consider this 
cohort separately. While several other miRNAs appeared 
differentially expressed in advanced samples in one cohort 
all of the results were not confirmed when combining 
the data of all cohorts. For example: while miR-10b-5p 
appeared highly expressed in advanced samples in 
the Charité and Würzburg cohorts it failed to show a 
statistically significant result in the cross cohort comparison 
(see Figure S2 for an overview of all miRNA expression 
patterns grouped into the single centres and combined).
miR-210-3p, which was not significantly regulated 
in pRCC in comparison to healthy control did show 
a statistically significantly lower expression in patients 
with localized tumors in comparison to healthy controls, 
while expression in patients with advanced tumors were 
comparable to healthy controls. ROC curve analysis 
resulted in an AUC of 0.708 for miR-210-3p, while miR-
21-5p did not result in significantly better AUC (0.574). A 
combined model including both miR-210-3p and miR-21-
5p slightly improved AUC in comparison to miR-210-3p 
alone (AUC: 0.718).
Discussion
The potential of circulating miRNAs as diagnostic and/
or prognostic biomarker has been investigated in RCC in 
the past years. However, these studies focussed on the most 
common subtype clear cell RCC (16,17). The analysis of 
serum/plasma miRNAs in pRCC patients was limited to few 
patients so far and these were usually part of a larger cohort 
comprising of patients with all histological subtypes (18-20). 
As a result, there is no reliable information regarding the 
relevance of circulating miRNAs in these patients. We thus 
studied serum miRNA expression in a multi-centre cohort 
including 67 pRCC patients and 33 healthy individuals.
We chose 11 miRNAs for analysis in serum samples 
based on their potential role as diagnostic (13,14) or 
pRCC type 1 vs. type 2 discriminative tissue markers (12) 
in tissue. Somewhat disappointingly we did not observe 
a significant different expression of any serum miRNA in 
patients with pRCC and healthy controls. However, miR-
21-5p levels were significantly increased in patients with 
advanced pRCC. In general, miR-21 is one of the most 
frequently upregulated miRNAs in solid malignancies (21) 
and considered to be a typical “onco-miR” as most of its 
targets are tumour suppressors (22). Notably, miR-21 serum 
levels were earlier correlated with advanced clinical stage 
in ccRCC patients (23). Tusong et al. further reported that 
serum miR-21 levels decreased following nephrectomy in 
patients with ccRCC (24). We thus assume that serum miR-
21 expression could be helpful to identify RCC patients 
with advanced disease.
Our study has several strengthens: the multi-centre 
designs allowed us to analyse the expression of serum 
miRNAs in a relevant number (n=67) of pRCC patients. In 
addition, the multi-centre setting stands out from most of 
earlier studies reported in patients with RCC so far. Finally, 
the quality control by analysing haemolysis-associated 
miRNAs (miR-23a-3p and miR-451a-5p) as well as the 
analysis of three reference miRNAs (miR-23a-3p, miR-
191-5p and miR-103a-3p) for normalization was superior to 
other studies in the field of RCC (16,17).
However, there are also limitations to this study. We 
did not perform global screening of miRNA expression 
in pRCC tissue in comparison to healthy controls. This 
resulted in lack of identifying a sensitive miRNA-based 
1319Translational Andrology and Urology, Vol 9, No 3 June 2020
  Transl Androl Urol 2020;9(3):1314-1322 | http://dx.doi.org/10.21037/tau.2020.03.18© Translational Andrology and Urology. All rights reserved.
Figure 2 Diagnostic power of miRNA expression in control vs. pRCC serum samples. (A) Principal component analysis (PCA) of 
normalized miR-expression in relation to control sera (red), pRCC type 1 (green) and type 2 sera (blue). (B) Hierarchical supervised 
clustering of normalized miR-expression in relation to control sera (red, left), pRCC type 1 (green, middle) and type 2 sera (blue, right). (C) 
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Figure 3 Association of miRNA expression and clinicopathological parameters in pRCC sera. (A) Normalized miR-21-5p and (B) miR-210-
3p expression in healthy control sera, localized and advanced pRCC disease, divided into the respective participating centers (left plots) and 
subsequent cross-cohort comparison (right plots). (C) AUC curves regarding the diagnostic accuracy of normalized miR-210-3p (left plot), 
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marker for pRCC detection and subtype differentiation. 
Our selection process was based on the hypothesis that 
upregulation of miRNA expression in pRCC tissue should 
be reflected by higher miRNAs serum levels. miRNAs can 
either be actively secreted by the miRNA-expressing cells in 
in vesicles or bound to Ago proteins or they can be passively 
released from apoptotic and necrotic cells (17). Passive 
release of miRNAs should result in serum miRNA levels 
reflecting the observed deregulation of miRNAs in tissue. 
Active release on the other hand will result in a different 
distribution of miRNAs in serum and tissue. Our findings 
report apparent discrepancies in tissue and serum, making a 
global screening in serum mandatory for the identification 
of potential non-invasive miRNA markers.
Our data also raise the question on whether serum 
miRNA serum levels are sensitive enough to be used as 
diagnostic markers. While we observed reduced miR-
210-3p serum levels in localized and elevated serum miR-
21 levels only in advanced cancers, the discriminative 
power of both miRNA biomarkers even in combination 
was moderate. We also observed an increased but not 
statistically significant elevation for a number of other 
miRNAs in advanced disease, raising the possibility that 
only few miRNAs will be released in sufficient levels to 
the blood stream to be suitable for cancer diagnosis. We 
will add however that we only studied a limited number of 
miRNAs. It might well be that we will identify miRNAs, 
whose levels are elevated in patients with early stage disease 
by global screening approaches in future studies. Further, 
we suggest the validation of our findings for miR-21-5p and 
miR-210-5p in a larger cohort.
Conclusions
The analysis of serum miRNAs did not provide diagnostic 
information in patients with pRCC and was not able to 
differentiate type 1 and type 2 subtypes. Serum miR-21-5p 
expression was increased in patients with advanced pRCC, 
whereas miR-210-3p expression was down-regulated in 
localized pRCC in our multicenter approach. We thus 
propose that these two miRs – after validation in larger 
patient cohorts—could be useful as prognostic biomarkers 
in this subtype of a clinically relevant disease.
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Figure S1 Normalized expression of all tested miRs in healthy control sera, pRCC type 1 and type 2 subtypes, divided into the respective 
participating centers (left plots) and subsequent cross-cohort comparison (right plots).
Figure S2 Normalized expression of all tested miRs in healthy control sera, localized and advanced pRCC disease, divided into the 
respective participating centers (left plots) and subsequent cross-cohort comparison (right plots).
